<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01559103</url>
  </required_header>
  <id_info>
    <org_study_id>D4430C00001</org_study_id>
    <nct_id>NCT01559103</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients</brief_title>
  <official_title>A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI5117 (Anti-IL-6)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Study to assess the safety and tolerability of MEDI5117 in Rheumatoid Arthritis patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Double-blind, Placebo-controlled, Randomized Study in Rheumatoid Arthritis Subjects to
      Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending
      Doses of MEDI5117 (anti-IL-6)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), physical examination, and safety laboratory variables.</measure>
    <time_frame>From Baseline up to 64 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics in terms of Maximum serum concentration (Cmax), time to Cmax (tmax), terminal rate constant(λz), terminal half-life (t1/2 λz).</measure>
    <time_frame>From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics in terms of area under the serum concentration-time curve from zero to the time of the last quantifiable concentration [AUC(0-t)] and from zero to infinity (AUC).</measure>
    <time_frame>From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacokinetics in terms of area under the serum concentration-time curve from zero to the time of concentration at Weeks 6 and 12 [AUC(0-6w) and AUC(0 12w)].</measure>
    <time_frame>From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Descriptions of pharmacokinetics in terms of systemic clearance (CL), volume of distribution during terminal phase (Vz), and volume of distribution at steady state (Vdss).</measure>
    <time_frame>From Day 1 Predose, 2h, 12h, 24h, day 7, week 2, 3, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48, 56 and week 64.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of pharmacodynamics in terms of total interleukin 6 (IL-6) and free IL-6 (exploratory) in plasma and high sensitive C-reactive protein (hs-CRP) pre and post MEDI5117 or placebo administration and their corresponding change from baseline.</measure>
    <time_frame>From Baseline day -1 to week 64</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of immunogenicity in terms of positive or negative for the presence of antidrug antibodies against MEDI5117 in blood.</measure>
    <time_frame>From Baseline day -1 to week 64</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>MEDI5117</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion administered over 60 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEDI5117 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous infusion administered over 60 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI5117</intervention_name>
    <description>Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg</description>
    <arm_group_label>MEDI5117</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MEDI5117 Placebo</intervention_name>
    <description>Intravenous infusion administered over 60 minutes</description>
    <arm_group_label>MEDI5117 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active Rheumatoid Arthritis (RA) for 6 months or more.

          -  Males or nonpregnant, nonlactating femails aged 20 to 75 years, inclusive.

          -  Body Mass Index (BMI) between 19 and 36 kg/m2 and weight between 50 and 145 kg,
             inclusive.

          -  Males, unless surgically sterile, must use 2 effective methods of birth control from
             Day 1 through follow-up.

        Exclusion Criteria:

          -  History or presence of any clinically significant disease or disorder which has not
             been stable over the previous 3 months.

          -  History of liver disease, bilirubin elevations, or Gilbert's Syndrome.

          -  Any systematic inflammatory condition in addition to RA (polymyalgia rheumatica, giant
             cell arthritis, systemic lupus, gout, pyrophosphate arthropathy).

          -  Current, chronic pain disorders including fibromyalgia and chronic regional pain
             syndromes or chronic fatigue syndromes.

          -  Intramuscular steroid injection or intraarticular steroid injection within 1 month of
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Posner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Astrazeneca, Waltham, MA, United States</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David J Bell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biokinetics, North Irland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joel Posner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Waltham, MA, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=1499&amp;filename=D4430C00001_Redacted_Clinical_Study_Report_Synopsis.pdf</url>
    <description>D4430C00001 Clinical Study Report Synopsis</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2012</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Phase I</keyword>
  <keyword>Biologic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

